190 related articles for article (PubMed ID: 36918098)
1. Living With Hereditary Angioedema in Australia: Findings From a National Observational Study Using Short Message Service to Monitor the Burden of Disease.
Katelaris CH; Boicos K; Button PH; McCloud PI; Burton PK; Perram FA; Youssef S; Tognarini D
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2457-2467.e1. PubMed ID: 36918098
[TBL] [Abstract][Full Text] [Related]
2. Modeling Cost-Effectiveness of On-Demand Treatment for Hereditary Angioedema Attacks.
Bernstein JA; Tyson C; Relan A; Adams P; Magar R
J Manag Care Spec Pharm; 2020 Feb; 26(2):203-210. PubMed ID: 31841366
[TBL] [Abstract][Full Text] [Related]
3. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
[TBL] [Abstract][Full Text] [Related]
4. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M
BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443
[TBL] [Abstract][Full Text] [Related]
5. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
[TBL] [Abstract][Full Text] [Related]
6. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
[TBL] [Abstract][Full Text] [Related]
7. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
8. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
[TBL] [Abstract][Full Text] [Related]
9. A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.
Kőhalmi KV; Veszeli N; Cervenak L; Varga L; Farkas H
Immunol Lett; 2017 Sep; 189():90-93. PubMed ID: 28577900
[TBL] [Abstract][Full Text] [Related]
10. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
[TBL] [Abstract][Full Text] [Related]
11. Hereditary angioedema with normal C1 inhibitor and factor XII mutation: a series of 57 patients from the French National Center of Reference for Angioedema.
Deroux A; Boccon-Gibod I; Fain O; Pralong P; Ollivier Y; Pagnier A; Djenouhat K; Du-Thanh A; Gompel A; Faisant C; Launay D; Bouillet L
Clin Exp Immunol; 2016 Sep; 185(3):332-7. PubMed ID: 27271546
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J
J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305
[TBL] [Abstract][Full Text] [Related]
13. C1-inhibitor therapy for hereditary angioedema attacks: prospective patient assessments of health-related quality of life.
Bewtra AK; Levy RJ; Jacobson KW; Wasserman RL; Machnig T; Craig TJ
Allergy Asthma Proc; 2012; 33(5):427-31. PubMed ID: 23026185
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children.
Reshef A; Grivcheva-Panovska V; Kessel A; Kivity S; Klimaszewska-Rembiasz M; Moldovan D; Farkas H; Gutova V; Fritz S; Relan A; Giannetti B; Magerl M
Pediatr Allergy Immunol; 2019 Aug; 30(5):562-568. PubMed ID: 30993784
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life among children with hereditary angioedema.
Engel-Yeger B; Farkas H; Kivity S; Veszeli N; Kőhalmi KV; Kessel A
Pediatr Allergy Immunol; 2017 Jun; 28(4):370-376. PubMed ID: 28258590
[TBL] [Abstract][Full Text] [Related]
17. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
Zanichelli A; Azin GM; Cristina F; Vacchini R; Caballero T
Orphanet J Rare Dis; 2018 Apr; 13(1):51. PubMed ID: 29631595
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema-A Long-Term Survey.
Farkas H; Kőhalmi KV; Visy B; Veszeli N; Varga L
J Allergy Clin Immunol Pract; 2020; 8(7):2379-2383. PubMed ID: 32198128
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor Deficiency.
Bork K; Bernstein JA; Machnig T; Craig TJ
J Emerg Med; 2016 Apr; 50(4):567-80.e1. PubMed ID: 26826769
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
